Related Experiment Video

Updated: Nov 29, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.6K

Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?

Umberto Vitolo1, Mattia Novo1, Elisa Santambrogio1

  • 1Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy.

British Journal of Haematology
|November 18, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BTK inhibitorsWaldenstrom macroglobulinemiaibrutinibprogression-free survivalresponse

More Related Videos

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.0K

Related Experiment Videos

Last Updated: Nov 29, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.6K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338

Articles linked to this work by shared authors, journal, and citation graph.

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Blood·2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

HemaSphere·2026

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review.

Frontiers in medicine·2026

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026

Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.

British journal of haematology·2026

Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients.

British journal of haematology·2026

Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study.

British journal of haematology·2026

Use of selective serotonin reuptake inhibitors and risk of myeloid malignancy: A nationwide Danish case-control study.

British journal of haematology·2026

Declining treatment-related and overall mortality in children with newly diagnosed advanced-stage non-Hodgkin lymphoma treated in a paediatric cancer centre during 2013-2024, Shanghai, China.

British journal of haematology·2026

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

British journal of haematology·2026

Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab.

Cureus·2026

Short-Term Intensive Insulin Therapy as a Remission Induction Strategy in Newly Diagnosed Type 2 Diabetes Mellitus: A Systematic Review.

Cureus·2026

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors.

ChemMedChem·2026

Invariant chain controls HLA-DQ folding and shapes the HLA class II proxiome.

Journal of immunology (Baltimore, Md. : 1950)·2026

Ultrasound-responsive PLGA nanoparticles co-loaded with celecoxib and catalase enhance the therapeutic efficacy of imatinib in gastrointestinal stromal tumors.

International journal of pharmaceutics·2026

Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma.

JHEP reports : innovation in hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us